Last reviewed · How we verify
Gan Fu Le Tablets
Gan Fu Le Tablets is a Small molecule drug developed by Shenzhen Kangzhe Pharmaceutical Co., Ltd.. It is currently in Phase 3 development for Liver dysfunction and hepatic support (traditional indication).
Gan Fu Le Tablets is a traditional Chinese medicine formulation designed to support liver function and promote hepatic health.
Gan Fu Le Tablets is a traditional Chinese medicine formulation designed to support liver function and promote hepatic health. Used for Liver dysfunction and hepatic support (traditional indication).
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Gan Fu Le Tablets |
|---|---|
| Sponsor | Shenzhen Kangzhe Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Therapeutic area | Hepatology |
| Phase | Phase 3 |
Mechanism of action
This herbal tablet formulation combines multiple botanical ingredients traditionally used in Chinese medicine to address liver dysfunction and support detoxification. The exact molecular mechanisms are not well-characterized in Western pharmacological terms, as the product represents a multi-component herbal preparation rather than a single-target drug. It is intended to improve liver metabolism and overall hepatic function.
Approved indications
- Liver dysfunction and hepatic support (traditional indication)
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gan Fu Le Tablets CI brief — competitive landscape report
- Gan Fu Le Tablets updates RSS · CI watch RSS
- Shenzhen Kangzhe Pharmaceutical Co., Ltd. portfolio CI
Frequently asked questions about Gan Fu Le Tablets
What is Gan Fu Le Tablets?
How does Gan Fu Le Tablets work?
What is Gan Fu Le Tablets used for?
Who makes Gan Fu Le Tablets?
What development phase is Gan Fu Le Tablets in?
Related
- Manufacturer: Shenzhen Kangzhe Pharmaceutical Co., Ltd. — full pipeline
- Therapeutic area: All drugs in Hepatology
- Indication: Drugs for Liver dysfunction and hepatic support (traditional indication)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing